Analytical and bioanalytical development of pixatimod (ZU545/PG545)- a clinical candidate for cancer with anti-viral and anti-inflammatory properties - to support clinical testing for Covid-19”
Fields of Study & Subjects
Analytical Methods in Pharmaceuticals
Biosimilars and Bioanalytical Methods
SARS-CoV-2 detection and testing
Publication details
- Journal / source
- Therapeutic Innovation Australia
- Publication date
- 16 February 2026
- Language
- EN